- Small biotech company appears to have key -
There may be a vaccine for the novel coronavirus by this time next year. That’s the hope of a small biotech company called Moderna.
The company, based in Cambridge, Mass., is known in the venture capital world as a “biotech unicorn.” A unicorn is a privately held startup company – Moderna is 10 years old – valued at $1 billion and, like the mythical unicorn, is a rare success in the business world.